COVID-19 testing

Southwest Research Institute (SwRI) has virtual screening software which it used to evaluate two million drug compounds agianst SARS-CoV-2. SwRI is partnered with Texas Biomedical Research Institute and their Rhodium software can scan 250,000 drug compounds using machine learning techniques.

Oak Ridge National Laboratory (ORNL) used its supercomputer to identify 77 small-molecule compounds as potential SARS-CoV-2 drugs which are likely to bind the novel coronavirus main spike protein which could prevent it from infecting cells.

Insilico Medicine is using an AI-based drug discovery pipeline to identify drug molecules that could target 3C-like protease. 3C-like protease is a SARS-CoV-2 protein that is a target for potential drugs because it has a central role in the viral replication cycle. A portion will be tested by Insilico Medicine and the remainder of the potentially useful structures will be published on the company website and available to the public (https://insilico.com/ncov-sprint/).

Insilico Medicine is using an AI-based drug discoverydrug discovery pipeline to identify drug molecules that could target 3C-like protease. 3C-like protease is a SARS-CoV-2 protein that is a target for potential drugs because it has a central role in the viral replication cycle. A portion will be tested by Insilico Medicine and the remainder of the potentially useful structures will be published on the company website and available to the public (https://insilico.com/ncov-sprint/).

Integrated DNA Technologies (IDT) is manufacturing virus detection panels and positive and negative controls for COVID-19 treatment and vaccine development.

Southwest Research Institute (SwRI) has virtual screening software which it used to evaluate two million drug compounds agianst SARS-CoV-2. SwRI is partnered with Texas Biomedical Research Institute and their Rhodium software can scan 250,000 drug compounds using machine learning techniques.

Oak Ridge National Laboratory (ORNL) used its supercomputer to identify 77 small-molecule compounds as potential SARS-CoV-2 drugs which are likely to bind the novel coronavirus main spike protein which could prevent it from infecting cells.

Insilico Medicine is using an AI-based drug discovery pipeline to identify drug molecules that could target 3C-like protease. 3C-like protease is a SARS-CoV-2 protein that is a target for potential drugs because it has a central role in the viral replication cycle. A portion will be tested by Insilico Medicine and the remainder of the potentially useful structures will be published on the company website and available to the public (https://insilico.com/ncov-sprint/).